M V Relling
Overview
Explore the profile of M V Relling including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
176
Citations
6233
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bank P, Caudle K, Swen J, Gammal R, Whirl-Carrillo M, Klein T, et al.
Clin Pharmacol Ther
. 2017 Oct;
103(4):599-618.
PMID: 28994452
Both the Clinical Pharmacogenetics Implementation Consortium (CPIC) and Dutch Pharmacogenetics Working Group provide therapeutic recommendations for well-known gene-drug pairs. Published recommendations show a high rate of concordance. However, as a...
2.
Relling M, Krauss R, Roden D, Klein T, Fowler D, Terada N, et al.
Clin Pharmacol Ther
. 2017 Aug;
102(6):897-902.
PMID: 28795399
The goal of pharmacogenomics research is to discover genetic polymorphisms that underlie variation in drug response. Increasingly, pharmacogenomics research involves large numbers of patients and the application of new technologies...
3.
Liu Y, Fernandez C, Relling M
Clin Pharmacol Ther
. 2017 Jul;
102(6):907.
PMID: 28744849
No abstract available.
4.
Inaba H, Pei D, Wolf J, Howard S, Hayden R, Go M, et al.
Ann Oncol
. 2017 Apr;
28(2):386-392.
PMID: 28426102
Background: Comprehensive studies on neutropenia and infection-related complications in patients with acute lymphoblastic leukemia (ALL) are lacking. Patients And Methods: We evaluated infection-related complications that were grade ≥3 on National...
5.
Eissa H, Zhou Y, Panetta J, Browne E, Jeha S, Cheng C, et al.
Blood Cancer J
. 2017 Feb;
7(2):e531.
PMID: 28212374
The impact of body mass index (BMI) at diagnosis on treatment outcome in children with acute lymphoblastic leukemia (ALL) is controversial. We studied 373 children with ALL enrolled on the...
6.
Karol S, Larsen E, Cheng C, Cao X, Yang W, Ramsey L, et al.
Leukemia
. 2017 Jan;
31(6):1325-1332.
PMID: 28096535
The causes of individual relapses in children with acute lymphoblastic leukemia (ALL) remain incompletely understood. We evaluated the contribution of germline genetic factors to relapse in 2225 children treated on...
7.
Liu Y, Fernandez C, Smith C, Yang W, Cheng C, Panetta J, et al.
Clin Pharmacol Ther
. 2017 Jan;
102(1):131-140.
PMID: 28090653
Remission induction therapy for acute lymphoblastic leukemia (ALL) includes medications that may cause hepatotoxicity, including asparaginase. We used a genome-wide association study to identify loci associated with elevated alanine transaminase...
8.
Luzum J, Pakyz R, Elsey A, Haidar C, Peterson J, Whirl-Carrillo M, et al.
Clin Pharmacol Ther
. 2017 Jan;
102(3):502-510.
PMID: 28090649
Numerous pharmacogenetic clinical guidelines and recommendations have been published, but barriers have hindered the clinical implementation of pharmacogenetics. The Translational Pharmacogenetics Program (TPP) of the National Institutes of Health (NIH)...
9.
Liu C, Yang W, Pei D, Cheng C, Smith C, Landier W, et al.
Clin Pharmacol Ther
. 2016 Aug;
101(3):373-381.
PMID: 27564568
We performed a genomewide association study (GWAS) of primary erythrocyte thiopurine S-methyltransferase (TPMT) activity in children with leukemia (n = 1,026). Adjusting for age and ancestry, TPMT was the only...
10.
Pui C, Pei D, Raimondi S, Coustan-Smith E, Jeha S, Cheng C, et al.
Leukemia
. 2016 Aug;
31(2):333-339.
PMID: 27560110
To determine the clinical significance of minimal residual disease (MRD) in patients with prognostically relevant subtypes of childhood acute lymphoblastic leukemia (ALL), we analyzed data from 488 patients treated in...